ENTRICULAR ARRHYTHMIAS IN HEART FAILURE PATIENTS WITH PRIMARY PREVENTION ICD IMPLANTATION

Thức Nguyễn Tri

Main Article Content

Abstract

Background: Ventricular arrhythmias are a major cause of sudden death in patients with heart failure and reduced ejection fraction. Implantable cardioverter-defibrillators are effective for primary prevention, but data in Vietnam are limited. Objective: To assess the incidence of ventricular arrhythmias recorded by implantable cardioverter-defibrillators in heart failure patients and analyze related factors. Method: A cross-sectional and longitudinal study was conducted on 59 patients with ejection fraction ≤ 35% who received implantable cardioverter-defibrillators from September 2020 to May 2021. Logistic regression was used for analysis. Result: During 7.8 months of follow-up, 35.6% developed ventricular arrhythmias (11.9% premature ventricular contractions, 5.1% nonsustained ventricular tachycardia, 11.9% sustained ventricular tachycardia). New York Heart Association class III was an independent risk factor (odds ratio 43.33; p = 0.006), while male sex (odds ratio 0.10; p = 0.006), beta-blocker use (odds ratio 0.08; p = 0.019), and cardiac resynchronization therapy with defibrillator (odds ratio 0.13; p = 0.025) were protective. Conclusion: Ventricular arrhythmias are common after implantable cardioverter-defibrillator implantation in heart failure patients. Symptom severity, sex, medication, and device type influence risk.

Article Details

References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. Jan 2022;24(1):4-131. doi:10.1002/ejhf.2333
2. Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev. Jul 2002;7(3):229-42. doi:10.1023/a:1020024122726
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. Jan 20 2005;352(3):225-37. doi:10.1056/NEJMoa043399
4. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. Sep 29 2016;375(13):1221-30. doi:10.1056/ NEJMoa1608029
5. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. Mar 21 2002;346(12): 877-83. doi:10.1056/ NEJMoa013474
6. Greenlee RT, Go AS, Peterson PN, et al. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network. J Am Heart Assoc. Mar 26 2018;7(7) doi:10.1161/jaha.117.008292
7. Satake H, Fukuda K, Sakata Y, et al. Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure--a report from the CHART-2 Study. Circ J. 2015;79(2):381-90. doi:10.1253/circj.CJ-14-0925
8. Kutyifa V, Klein HU, Wang PJ, et al. Clinical significance of ventricular tachyarrhythmias in patients treated with CRT-D. Heart Rhythm. Jul 2013;10(7): 943-50. doi:10.1016/j.hrthm. 2013.04.006